GENB stock news · Generate Biomedicines
Get alerts for GENB
Follow Generate Biomedicines (GENB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GENBFree on the App Store and Google Play, or on the web.
Morgan Stanley lowered its price target for Generate Biomedicines from $22 to $21.
NeutralMorgan Stanley cut its GENB target from $22 to $21 but kept its favorable rating. The mixed update does not clearly change the company's outlook.
Generate Biomedicines teams up with Zealand Pharma to create AI drugs for the growing obesity market.
Good for GENBGenerate Biomedicines has a new drug-development partnership that brings upfront cash and possible future payments. The later payments depend on progress, so the deal is a positive step, not a sure payoff.